Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;21(1):44-50.
doi: 10.3747/co.21.1871.

Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence

R A Wells  1 , B Leber  2 , N Y Zhu  3 , J M Storring  4
Affiliations

Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence

R A Wells et al. Curr Oncol. 2014 Feb.

Abstract

Myelodysplastic syndromes (mdss) constitute a heterogeneous group of malignant hematologic disorders characterized by marrow dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, and pronounced risk of progression to acute myeloid leukemia. Azacitidine has emerged as an important treatment option and is recommended by the Canadian Consortium on Evidence-Based Care in mds as a first-line therapy for intermediate-2 and high-risk patients not eligible for allogeneic stem cell transplant; however, practical guidance on how to manage patients through treatment is limited. This best practice guideline provides recommendations by a panel of experts from Canadian centres of excellence on the selection and clinical management of mds patients with azacitidine. Familiarity with the referral process, treatment protocols, dose scheduling, treatment expectations, response monitoring, management of treatment breaks and adverse events, and multidisciplinary strategies for patient support will improve the opportunity for optimizing treatment outcomes with azacitidine.

Keywords: 5-azacitidine; Myelodysplastic syndrome; Vidaza; clinical outcomes; guidelines; mds; practical recommendations.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Nguyen PL. The myelodysplastic syndromes. Hematol Oncol Clin North Am. 2009;23:675–91. doi: 10.1016/j.hoc.2009.04.008. - DOI - PubMed
    1. Buckstein R, Yee K, Wells RA, on behalf of the Canadian Consortium on Evidence-Based Care in mds 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline. Cancer Treat Rev. 2011;37:160–7. doi: 10.1016/j.ctrv.2010.05.006. - DOI - PubMed
    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88. - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. doi: 10.1182/blood-2012-03-420489. - DOI - PMC - PubMed
    1. Abel GA, Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol. 2013;20:150–6. doi: 10.1097/MOH.0b013e32835d8e8e. - DOI - PubMed

LinkOut - more resources